Herpes simplex virus (HSV) is a master of persistence. Once the initial infection fades, the virus doesn’t leave the body—it simply retreats into a kind of sleep. This dormant state, called latency, is one of HSV’s defining features. During latency, the virus hides out in the sensory neurons, tucking itself away from the immune system by limiting gene expression, especially through a molecule known as the latency-associated transcript (LAT). It’s a biological strategy designed for survival, one that allows HSV to remain undetected for long stretches of time.
But the virus doesn’t stay silent forever. Reactivation is the process by which HSV “wakes up,” shifting from this quiet latency into active replication. This change is often sparked by stress within the body—both at a cellular level and a broader physical or emotional level. When that happens, the virus can travel back down nerve pathways to the skin or mucous membranes, potentially causing a visible outbreak or, in some cases, silently shedding virus without symptoms.
It’s important to distinguish between what causes herpes and what triggers it. The cause is straightforward: infection with HSV-1 or HSV-2. Once you’re infected, the virus becomes a lifelong companion. Triggers, on the other hand, are the internal or external factors—like UV light, emotional stress, or illness—that can stir the virus from its dormant state. These don’t cause herpes; rather, they shift the cellular environment in ways that allow the virus to reactivate.
This post explores what’s happening beneath the surface—at the level of neurons, molecules, and stress signals. We’ll look at the mechanisms that make reactivation possible and the science behind why some people experience outbreaks while others do not. By understanding how triggers work, we move closer to managing—and anticipating—the rhythms of this complex virus.
Understanding Viral Latency – Where the Virus Hides
Once HSV enters the body, it doesn’t stay at the surface. After causing an initial outbreak—often around the mouth or genitals—the virus makes its way along nerve pathways to sensory ganglia deep within the body. These clusters of nerve cells, such as the trigeminal ganglia (linked to oral infections) or the dorsal root ganglia (more often involved in genital cases), become long-term sanctuaries for the virus.
Inside these neurons, HSV adopts a dormant state known as latency. The viral DNA takes on a circular form and tucks itself into the cell’s nucleus, where it stops producing most of its proteins. The only part that stays active is a region called the latency-associated transcript, or LAT. This molecule isn’t involved in making new viruses—it actually helps keep the virus silent. LAT prevents the host cell from undergoing apoptosis (a form of programmed cell death) and suppresses viral genes that would otherwise kickstart a new round of infection. In essence, LAT helps HSV stay hidden and alive.
One of HSV’s greatest tricks is how well it avoids the immune system during this phase. Because it isn’t producing the usual viral proteins, it becomes almost invisible to immune surveillance. Immune cells that normally patrol the body for signs of infection—especially CD8+ T cells—can’t easily detect or target latent HSV. The virus even undermines these cells by exhausting their ability to release key immune signals, like interferon-gamma. Meanwhile, HSV also subtly manipulates the neuron’s own defense mechanisms, interfering with pathways that would normally alert the immune system.
This stealth makes herpes a lifelong infection. The virus remains tucked away in the nervous system, shielded from both antiviral drugs and immune attack. While medications like acyclovir can prevent or shorten outbreaks by targeting active replication, they have no effect on the latent virus. That’s why herpes isn’t curable—but it is controllable. The immune system, particularly those same CD8+ T cells, continues to monitor and suppress the virus, helping reduce the frequency and intensity of reactivations. With proper care, many people experience long stretches without symptoms, even though the virus remains with them for life.
Reactivation 101 – How Dormant HSV Awakens
Herpes doesn’t stay asleep forever. Though it lies quietly within neurons during latency, the virus can suddenly reawaken—often without warning. This reactivation is a carefully orchestrated biological process, not a random flare. At its core, it begins when the virus lifts the molecular silence that had kept its genes repressed.
During latency, the HSV genome is packed into a tight structure called heterochromatin, which keeps most viral genes switched off. Reactivation starts when this repression is undone, beginning with the expression of immediate-early genes. This marks what scientists call Phase I—a preparatory stage where the virus starts building the machinery it needs without yet replicating its DNA. It’s the first step toward creating new viral particles that can travel out of the neuron and back into the body’s surface tissues.
But what prompts the virus to stir? Often, it’s stress—not just the emotional kind, but stress at the cellular level. Neurons experiencing injury, inflammation, or metabolic strain activate a molecular cascade known as the DLK/JNK pathway. This pathway acts like a cellular alarm bell, sending signals that shift the viral genome out of its silenced state. Even inflammatory molecules like interleukin-1 (IL-1) can make neurons hyperexcitable, further pushing HSV toward reactivation. Deprivation of supportive factors—like nerve growth factor—or disruption of critical signaling pathways such as PI3K/Akt can also tip the balance, unlocking the virus from its dormant state.
Once HSV is active again, it doesn’t stay put. Newly formed viral particles travel along the neuron’s axon—the long fiber that connects the cell body to skin or mucous membranes. This journey uses the cell’s internal transport system, a kind of microscopic railway made of microtubules. The virus hitches a ride via anterograde axonal transport, guided by viral proteins that help it reach the body’s surface. There, it can cause visible symptoms or quietly shed, spreading the virus without obvious signs.
Not every reactivation leads to an outbreak. If the transport process fails or immune responses step in quickly, the virus might be stopped before it reaches the surface. But when the system works in the virus’s favor, reactivation becomes more than just a silent shift in the neuron—it becomes a contagious, visible event.
The Biology of Triggers – What Really Causes an Outbreak?
Triggers don’t cause herpes, but they do help explain why the virus sometimes reactivates after long periods of silence. These triggers—ranging from stress to sunlight—act on the body in ways that alter immune balance, increase cellular stress, or weaken natural defense systems. Below, we break down the major biological pathways that allow these triggers to disturb latency and awaken HSV.
Immune Suppression: When the Body’s Guard Is Down
Our immune system constantly monitors for signs of HSV reactivation. But when that surveillance weakens—whether from illness, medication, or chronic health conditions—the virus finds an opportunity to reemerge.
Common infections like the flu or COVID-19 can tip the immune balance by overloading the system or disrupting cytokine regulation. Immunosuppressive medications, such as those used for autoimmune diseases or post-transplant care, reduce the activity of immune cells needed to keep HSV in check. These changes don’t directly “activate” the virus—they create the conditions where HSV can slip past the body’s defenses.
A key part of this vulnerability lies in T-cell fatigue. Over time, chronic exposure to HSV leads to exhaustion in CD8+ T cells, the immune system’s viral enforcers. These cells lose their potency, becoming less able to produce antiviral molecules like interferon-gamma or TNF-alpha. The virus exploits this, using immune checkpoint molecules (like PD-1 and TIM-3) to further disarm the body’s response. This immunological fatigue is what turns a watchful immune system into a permissive one.
Cortisol & Stress Hormones: How Emotional Strain Becomes a Viral Cue
Stress is more than a feeling—it’s a physiological state that affects every system in the body, including the nervous and immune systems. Prolonged mental or physical stress elevates cortisol, a hormone that suppresses inflammation but also weakens immune surveillance.
At the cellular level, cortisol binds to the glucocorticoid receptor (GR) in neurons and immune cells. This interaction can promote the activation of HSV’s lytic genes by enhancing transcriptional co-activators like KLF4 and SLUG. Even without a full immune collapse, stress can nudge the virus out of latency by making neurons more electrically active—a process linked to the DLK/JNK signaling pathway.
The hypothalamic-pituitary-adrenal (HPA) axis, which regulates cortisol, plays a major role in this stress response. When dysregulated, it can suppress T-cell activity and increase vulnerability to infection. In effect, stress becomes a double-edged sword: it dampens immune defenses and directly supports the virus’s ability to switch back on.
Hormonal Fluctuations: The Menstrual Cycle and Beyond
Hormones influence more than mood—they also affect immune readiness. For people with menstrual cycles, fluctuations in estrogen and progesterone levels can create windows of reduced mucosal immunity. Around menstruation, dips in estrogen can weaken the vaginal barrier and alter immune cell composition, increasing the likelihood of HSV reactivation.
Beyond the reproductive system, hormone receptors on immune cells help regulate antiviral responses. Changes in hormone levels can modulate these receptors, either strengthening or weakening the body’s ability to suppress HSV. Stress hormones and sex hormones also interact, compounding their effects on immune cell function and viral control.
UV Radiation & Skin Damage: Sunlight as a Cellular Stressor
For those with oral HSV, sunlight is a well-known trigger. Exposure to UV-B radiation doesn’t just damage the skin—it disrupts local immunity. Antigen-presenting cells in the skin become less active, and cytokine levels drop, weakening the body’s frontline defenses.
Damaged skin cells also release inflammatory signals like IL-1β and IL-6. These molecules activate stress-response pathways in nearby neurons, particularly DLK/JNK, which are known to kickstart HSV reactivation. This can explain why a sunburn on the lip or face often precedes a cold sore: the environmental stress accumulates, and a single neuron flips the viral switch.
Nutrient Deficiencies: Fueling or Starving the Virus
The balance of nutrients in the body can influence HSV’s ability to reactivate and replicate. Lysine, zinc, and vitamin D are particularly important for antiviral defense. Lysine can interfere with arginine uptake, a critical amino acid for HSV replication. Zinc helps maintain T-cell function and directly inhibits viral enzymes. Vitamin D supports antimicrobial peptides and modulates cytokine production, helping the immune system stay primed.
On the flip side, diets high in arginine—found in foods like nuts, oats, and chocolate—may tip the balance in the virus’s favor. HSV relies on arginine for building new proteins, and when this amino acid is abundant, the virus may replicate more easily. The exact impact of diet varies by individual, but the underlying biology shows that nutrition can quietly shape the body’s readiness for outbreaks.
These triggers don’t act in isolation. Often, it’s a combination—stress, illness, and poor sleep, for instance—that pushes HSV from latency into activity. Understanding how each factor works offers not just insight, but also agency. With awareness comes the ability to reduce risk and recognize your own patterns of reactivation.
Why Reactivation Doesn’t Always Mean Symptoms
One of the more confounding aspects of herpes is that the virus can reactivate without ever announcing its presence. Many people assume outbreaks are the only sign that HSV is active, but the truth is far more nuanced. The virus often reawakens silently, a phenomenon known as asymptomatic viral shedding—and it plays a central role in how HSV spreads.
Studies have shown that a significant portion of herpes transmission—up to 70%—occurs during these symptom-free periods. People who don’t experience classic signs like sores or blisters may still shed virus from mucosal surfaces, particularly the genitals or mouth. This means that even individuals who have never had a noticeable outbreak can still carry and transmit HSV. Shedding episodes are typically brief and go unnoticed, as the virus may be present only for a few hours and doesn’t always reach the skin with enough force to cause a visible lesion.
Whether reactivation leads to symptoms depends on several biological factors. The immune system often plays a gatekeeping role: when functioning well, it can limit the virus’s journey from the nerve cell to the skin, containing reactivation at the site of origin. Memory CD8+ T cells in nearby tissues add another layer of defense, helping to suppress viral replication before it becomes clinically visible. Outbreaks become more likely when this surveillance falters—due to stress, illness, hormonal changes, or a high viral load reaching the surface.
For some, the earliest sign of an outbreak isn’t a sore—it’s a sensation. Known as prodromal symptoms, these include tingling, itching, or burning in the area where lesions usually appear. Recognizing these cues can be key. They offer a window for early intervention, when antiviral medication can be most effective in reducing the severity and duration of symptoms, as well as limiting viral shedding.
Learning to identify prodromal signs can take time, especially for those newly diagnosed or previously unaware of their infection. But awareness makes a difference. It helps individuals respond quickly, lowers the chances of transmission, and empowers them to manage reactivation on their own terms.
Why Triggers Are Different for Everyone
If you’ve ever wondered why some people with herpes experience frequent outbreaks while others rarely notice a symptom, the answer lies in biology—and it’s deeply personal. The factors that govern HSV reactivation are influenced by everything from genetics to lifestyle, making each person’s experience with the virus uniquely their own.
A major piece of the puzzle is genetic variation in the immune system. Some people inherit immune receptors—like certain forms of killer-cell immunoglobulin-like receptors (KIRs)—that make them more prone to symptomatic outbreaks. Others may have subtle changes in genes that govern chemokine signaling, like the CXCL10/CXCR3 pathway, which helps direct T cells to infected tissues. When these pathways function poorly, the immune system may struggle to contain the virus, leading to more frequent or severe reactivations.
But genetics don’t just shape the immune response—they also influence how the virus behaves. HSV-1 and HSV-2 are genetically distinct, and each has a preference for different parts of the nervous system. HSV-1 tends to reactivate from the trigeminal ganglia, which innervates the face, while HSV-2 typically lies dormant in the sacral ganglia near the base of the spine, affecting the genitals. Even within these types, individual viral strains vary in how easily they reactivate, how quickly they replicate, and how strongly they provoke the immune system.
The specific nerve ganglia affected also matter. Different ganglia create different local environments—some are more heavily patrolled by immune cells, others less so. This can influence how often the virus is able to escape and travel back to the skin or mucosa. Combined with the unique characteristics of the viral strain, this adds another layer of individuality to how herpes manifests.
Lifestyle factors further complicate the picture. Chronic stress, poor sleep, and nutritional imbalances can all chip away at the body’s ability to keep HSV in check. Underlying health conditions—like diabetes, autoimmune diseases, or HIV—can also weaken immune surveillance, making reactivation more likely. Even among people with similar infections, those with stronger baseline immune activity, particularly a robust presence of CD8+ T cells in key neural tissues, may experience fewer symptoms over time.
In short, no two people live with herpes in exactly the same way. Biology, environment, and behavior all intersect to shape an individual’s reactivation risk. Recognizing this complexity not only helps reduce stigma—it empowers people to understand and manage their own experience with greater clarity and compassion.
How to Reduce Reactivation Risk Scientifically
Living with herpes doesn’t mean living at the mercy of the virus. While HSV is a lifelong presence, science offers practical strategies to reduce the likelihood of reactivation—and with it, outbreaks and transmission. By understanding how herpes interacts with your immune system, daily habits, and treatment choices, it becomes possible to manage reactivation risk more effectively.
Building Immune Resilience: The Foundation of Prevention
At the heart of herpes suppression is the immune system. When it’s functioning well, the body can often contain the virus before symptoms emerge. But this balance is fragile. Chronic psychological stress, for instance, doesn’t just affect mood—it disrupts immune regulation and triggers inflammatory activity in neurons, both of which can reactivate HSV. Prioritizing stress management through practices like mindfulness, exercise, or therapy can help reduce this vulnerability.
Sleep is another often-overlooked pillar. Inadequate rest hampers the function of natural killer cells and weakens T-cell responses, leaving the body less prepared to intercept viral activity. Ensuring consistent, high-quality sleep supports immune surveillance at a cellular level.
Diet also plays a subtle but significant role. Nutrient deficiencies—particularly in lysine, zinc, and vitamin D—can weaken antiviral defenses. At the same time, high intake of arginine-rich foods may support viral replication. While not everyone is affected the same way, staying mindful of these nutritional factors can support broader immune health and reduce the likelihood of reactivation.
Medical Prevention: When Suppressive Therapy Makes Sense
For those with frequent outbreaks or concerns about transmission, daily antiviral medication offers a reliable line of defense. Drugs like valacyclovir have been shown to significantly reduce both symptomatic episodes and viral shedding. They’re especially helpful for people who experience frequent or severe outbreaks, or who are in intimate relationships where one partner is HSV-negative.
Emerging antiviral agents like SC93305 show promise for managing drug-resistant strains of HSV, offering potential new options for long-term suppression with fewer side effects. Prophylactic treatment is also a key strategy for individuals with compromised immune systems, such as transplant recipients or people undergoing chemotherapy, where the risk of severe reactivation is higher.
Personal Tracking: Knowing Your Own Patterns
Perhaps one of the most empowering tools in herpes management is self-awareness. HSV reactivation isn’t random—it often follows patterns that, once recognized, can be anticipated and managed. Some people experience viral shedding on as many as three-quarters of days, though not all of those days lead to symptoms.
Tracking symptoms, triggers, and prodromal sensations like tingling or itching can help individuals spot early signs of an outbreak. This awareness makes it easier to start antiviral treatment promptly, potentially shortening or even halting the episode. Keeping a diary or using a digital tracker to log factors like stress, sleep, menstrual cycles, and diet can help identify personal reactivation windows and improve long-term control.
In the end, reducing HSV reactivation isn’t about eliminating all risk—it’s about understanding the science, listening to your body, and making informed choices that support your health and peace of mind.
Your Body, Your Rhythm: Understanding HSV on Your Terms
Living with herpes means learning to coexist with a virus that doesn’t always follow predictable rules. But as science continues to shed light on how HSV reactivates—and what influences that process—it becomes easier to shift from feeling reactive to being prepared. The triggers that lead to outbreaks aren’t signs of personal failure; they’re reflections of complex biological interactions involving stress, immunity, hormones, and individual genetics. What affects one person might not affect another—and that’s not only normal, it’s expected.
By understanding the inner workings of latency and reactivation, you can begin to see patterns, make sense of your experiences, and find strategies that support your unique needs. Whether that means adjusting your diet, tracking your symptoms, managing stress, or working with a provider on antiviral therapy, there are many tools available—and you deserve access to all of them.
If you’d like more science-backed guidance, compassionate resources, and updates from our team, we invite you to join our mailing list. You’ll be the first to hear about new articles and tools designed to help you stay informed, supported, and empowered.
References
Álvarez, D. M., Castillo, E., Duarte, L., Arriagada, J., Corrales, N., Farías, M. A., Henríquez, A., Agurto-Muñoz, C., & González, P. (2020). Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection. Frontiers in Microbiology.
Chentoufi, A. A., Kritzer, E., Tran, M., Dasgupta, G., Lim, C. H., Yu, D. C., Afifi, R. E., Jiang, X., Carpenter, D., Osorio, N., Hsiang, C., Nesburn, A. B., Wechsler, S. L., & BenMohamed, L. (2011). The Herpes Simplex Virus 1 Latency-Associated Transcript Promotes Functional Exhaustion of Virus-Specific CD8+ T Cells. Journal of Virology, 85, 9127–9138.
Cliffe, A. R., & Wilson, A. C. (2017). Restarting Lytic Gene Transcription at the Onset of Herpes Simplex Virus Reactivation. Journal of virology, 91(2), e01419-16.
Cliffe, A. R., Arbuckle, J. H., Vogel, J. L., Geden, M. J., Rothbart, S. B., Cusack, C. L., Strahl, B. D., Kristie, T. M., & Deshmukh, M. (2015). Neuronal Stress Pathway Mediating a Histone Methyl/Phospho Switch Is Required for Herpes Simplex Virus Reactivation. Cell host & microbe, 18(6), 649–658.
Cuddy, S. R., Schinlever, A. R., Dochnal, S., Suzich, J. B., Farah, M., Boutell, C., & Cliffe, A. (2020). Reactivation of Herpes Simplex Virus (HSV) from Latency in Response to Neuronal Hyperexcitability. Proceedings.
Dochnal, S., Merchant, H. Y., Schinlever, A. R., Babnis, A., Depledge, D. P., Wilson, A. C., & Cliffe, A. R. (2022). DLK-Dependent Biphasic Reactivation of Herpes Simplex Virus Latency Established in the Absence of Antivirals. Journal of virology, 96(12), e0050822.
Estefanía, E., Gómez-Lozano, N., Portero, F., de Pablo, R., Solís, R., Sepúlveda, S., Vaquero, M., González, M. A., Suárez, E., Roustán, G., & Vilches, C. (2007). Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue antigens, 70(1), 34–41.
Harrison, K. S., & Jones, C. (2022). Regulation of herpes simplex virus type 1 latency-reactivation cycle and ocular disease by cellular signaling pathways. Experimental eye research, 218, 109017.
Hoshino, Y., Pesnicak, L., Cohen, J. I., & Straus, S. E. (2007). Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells. Journal of virology, 81(15), 8157–8164.
Imafuku S. (2023). Recent advance in management of herpes simplex in Japan. The Journal of dermatology, 50(3), 299–304.
Kobayashi, M., Kim, J.-y., Camarena, V., Roehm, P., Chao, M., Wilson, A. C., & Mohr, I. (2012). A primary neuron culture system for the study of herpes simplex virus latency and reactivation. Journal of Visualized Experiments, 62.
Koelle, D. M., Benedetti, J., Langenberg, A., & Corey, L. (1992). Asymptomatic Reactivation of Herpes Simplex Virus in Women after the First Episode of Genital Herpes. International Journal of Gynecology & Obstetrics, 39.
Koelle, D. M., & Wald, A. (2000). Herpes simplex virus: the importance of asymptomatic shedding. The Journal of Antimicrobial Chemotherapy, 45(Suppl T3), 1–8.
Krichevskaya, G., Sorozhkina, E., Balatskaya, N., Kovaleva, L. A., & Davydova, G. A. (2024). The significance of reactivation of latent herpes simplex viruses type 1 and 2. Russian Ophthalmological Journal.
Kriesel, J. D., Gebhardt, B. M., Hill, J. M., et al. (1997). Anti-interleukin-6 antibodies inhibit herpes simplex virus reactivation. The Journal of Infectious Diseases, 175(4), 821–827.
Lonsdale, D. M., Brown, S. M., Lang, J., Subak-Sharpe, J. H., Koprowski, H., & Warren, K. G. (1980). Variations in herpes simplex virus isolated from human ganglia and a study of clonal variation in HSV-1. Annals of the New York Academy of Sciences, 354, 291–308.
Low-Calle, A. M., Prada-Arismendy, J., & Castellanos, J. E. (2014). Study of interferon-β antiviral activity against Herpes simplex virus type 1 in neuron-enriched trigeminal ganglia cultures. Virus research, 180, 49–58.
Marcocci, M. E., Napoletani, G., Protto, V., Kolesova, O., Piacentini, R., Li Puma, D. D., Lomonte, P., Grassi, C., Palamara, A. T., & De Chiara, G. (2020). Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends in microbiology, 28(10), 808–820.
Mertz, G. (2008). Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. The Journal of Infectious Diseases, 198(8), 1098–1100.
Nicoll, M. P., Proença, J. T., & Efstathiou, S. (2012). The molecular basis of herpes simplex virus latency. FEMS microbiology reviews, 36(3), 684–705.
Norberg, A., Norberg, P. R. B. M., Manhães, F. C., Mangiavacchi, B. M., de Siqueira Filho, A. T., da Silva, S. C., Souza, A. H., Souza, A. P. I. F., Ferreira Filho, R. M., & Borges, T. R. B. (2023). Herpes Simplex Virus (HSV) Reactivation in COVID-19 Patients: A Mini Systematic Review. Journal of Advances in Medicine and Medical Research.
Ostler, J. B., Sawant, L., Harrison, K., & Jones, C. (2021). Regulation of neurotropic herpesvirus productive infection and latency-reactivation cycle by glucocorticoid receptor and stress-induced transcription factors. Vitamins and hormones, 117, 101–132.
Ostler, J. B., Thunuguntla, P., Hendrickson, B. Y., & Jones, C. (2021). Transactivation of Herpes Simplex Virus 1 (HSV-1) Infected Cell Protein 4 Enhancer by Glucocorticoid Receptor and Stress-Induced Transcription Factors Requires Overlapping Krüppel-Like Transcription Factor 4/Sp1 Binding Sites. Journal of virology, 95(4), e01776-20.
Perna, J. J., Mannix, M. L., Rooney, J. F., Notkins, A. L., & Straus, S. E. (1987). Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model. Journal of the American Academy of Dermatology, 17(3), 473–478.
Retamal-Díaz, A. R., Suazo, P. A., Garrido, I., Kalergis, A. M., & González, P. A. (2015). Evasión de la respuesta inmune por virus herpes simplex [Immune evasion by herpes simplex viruses]. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 32(1), 58–70.
Santos, V. C., Ostler, J. B., Harrison, K. S., & Jones, C. (2023). Slug, a Stress-Induced Transcription Factor, Stimulates Herpes Simplex Virus 1 Replication and Transactivates a cis-Regulatory Module within the VP16 Promoter. Journal of virology, 97(4), e0007323.
Shimeld, C., Whiteland, J. L., Williams, N. A., Easty, D. L., & Hill, T. J. (1996). Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion. The Journal of General Virology, 77(Pt 10), 2583–2590.
Srivastava, R., Dervillez, X., Khan, A. A., Chentoufi, A. A., Chilukuri, S., Shukr, N., Fazli, Y., Ong, N. N., Afifi, R. E., Osorio, N., Geertsema, R., Nesburn, A. B., Wechsler, S. L., & BenMohamed, L. (2016). The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8+ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits. Journal of virology, 90(8), 3913–3928.
Srivastava, R., Khan, A. A., Chilukuri, S., Syed, S. A., Tran, T. T., Furness, J. N., Bahraoui, E., & BenMohamed, L. (2017). CXCL10/CXCR3-dependent mobilization of herpes simplex virus-specific CD8+ T cells allows efficient protection against recurrent herpesvirus infection and disease. Journal of Virology, 91(17).
St Leger, A. J., Koelle, D. M., Kinchington, P. R., & Verjans, G. M. G. M. (2021). Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man. Frontiers in immunology, 12, 723809.
Sun, B., Wang, Q., & Pan, D. (2019). Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 48(1), 89–101.
Sun, J., Yan, C.-Y., Niu, J., Pan, M., Luo, Z., Duan, W.-J., Li, W., Wu, Y., Sun, W.-Y., Huang, F., Liu, F.-N., Liu, H., Kurihara, H., Li, Y.-F., & He, R. (2022). Latent herpes simplex virus type 1 reactivation increases the susceptibility of neurodegenerative diseases. Acta Materia Medica.
Suzich, J. B., & Cliffe, A. R. (2018). Strength in diversity: Understanding the pathways to herpes simplex virus reactivation. Virology, 522, 81–91.
Thellman, N. M., & Triezenberg, S. J. (2017). Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency. Pathogens (Basel, Switzerland), 6(3), 28.
Thompson, R. L., & Sawtell, N. M. (2011). The herpes simplex virus type 1 latency associated transcript locus is required for the maintenance of reactivation competent latent infections. Journal of neurovirology, 17(6), 552–558.
Ventura, A., Merajver, S., Shew, M., Kahn, J., DeKruyff, R., & Umetsu, D. (2013). HSV reactivation: HSV DNA in sensory ganglia neurons directs synthesis of proteins needed for HSV replication.
Wald, A., Zeh, J., Selke, S., Warren, T., Ryncarz, A., Ashley, R., Krieger, J., & Corey, L. (2000). Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. The New England Journal of Medicine, 342(12), 844–850.
Whitford, A. L., Clinton, C. A., Kennedy, E. B. L., Dochnal, S. A., Suzich, J. B., & Cliffe, A. R. (2022). Ex Vivo Herpes Simplex Virus Reactivation Involves a Dual Leucine Zipper Kinase-Dependent Wave of Lytic Gene Expression That Is Independent of Histone Demethylase Activity and Viral Genome Synthesis. Journal of virology, 96(12), e0047522.
Zinser, E., Krawczyk, A., Mühl-Zürbes, P., Aufderhorst, U., Draßner, C., Stich, L., Zaja, M., Strobl, S., Steinkasserer, A., & Heilingloh, C. S. (2018). A new promising candidate to overcome drug resistant herpes simplex virus infections. Antiviral research, 149, 202–210.
